Introduction
An enduring notion in the medicinal Cannabis and cannabinoid field is that of entourage: the idea that use of the whole plant may exert substantially greater effects than the sum of its individual parts. 1 Entourage is usually construed as a positive attribute, with the assumption that superior therapeutic actions, or a more favourable "high", will be obtained from consuming the whole Cannabis plant rather than individual components such as ∆ 9 -tetrahydrocannabinol (THC). Somewhat surprisingly, the evidence for this widely cited notion is relatively sparse.
Cannabis contains almost 150 phytocannabinoids, the most common of which are THC and cannabidiol (CBD), together with their acid precursors THCA and CBDA 2 . Cannabis also contains a large number of monoterpene and sesquiterpene compounds (together called terpenoids), the most common of which include α-pinene, β-pinene, linalool, limonene and β-myrcene (monoterpenes) and β-caryophyllene and caryophyllene oxide (sesquiterpenes). 3 Terpenoids are volatile compounds that are synthesised alongside phytocannabinoids mainly in the trichomes of the cannabis plant, and provide cannabis with its distinctive aroma and flavour. 4 Terpenoids are often lost if the extraction process involves heating. 5 The entourage concept applied to cannabis can encompass the potential for both cannabinoidcannabinoid and cannabinoid-terpenoid interactions. With regard to the former, ∆ 9 -THC-CBD synergy in producing analgesia was reported in an animal model of neuropathic pain 6 while in humans, CBD has been proposed to ameliorate some of the adverse psychotomimetic and anxiogenic effects of ∆ 9 -THC. 7, 8 This claim is controversial, however, with a number of contrary findings 9, 10 CBD may modulate ∆ 9 -THC effects at the receptor level acting as a CB 1 negative allosteric modulator 11 , providing some biological plausibility to a modulatory interaction. With so many bioactive components present in cannabis, the systematic, granular elucidation of possible entourage effects poses a substantial combinatorial puzzle and scientific challenge. As a preliminary approach to addressing this challenge, the present study examined whether the effects of ∆ 9 -THC on its cognate cannabinoid receptors (CB 1 and CB 2 ) would be modified in the presence of terpenoids that are commonly found in cannabis, either alone or in combination. The demonstration of such a receptor-level entourage effect might lead to predictions regarding functional cannabinoid-terpenoid interaction effects that could be tested in vivo.
Materials and Methods

Cell culture
Experiments used mouse wild-type AtT20 FlpIn cells (AtT20-WT), or these cells stably transfected with human CB 1 or CB 2 receptors with 3x N-terminus haemagglutinin tags (AtT20-CB 1 and AtT20-CB 2 respectively). 17 Cells were cultivated in Dulbecco's Modified Eagle's Medium (DMEM; Sigma-Aldrich) supplemented with 10% foetal bovine serum (FBS; SIGMA/SAFC) and 100U penicillin/100µg streptomycin mL -1 (Gibco). Selection antibiotics were 80µg mL -1 Zeocin (Invivogen) for AtT20-WT or 80µg mL -1 hygromycin B Gold (Invivogen) for transfected cells.
Cells were grown in 75mm 2 flasks at 37°C/5% CO 2 and passaged when 80-90% confluent. Assays were carried out on cells up to 20 passages in culture.
Potassium Channel Activity Measurements
Changes in membrane potential were measured using the FLIPR ® blue membrane potential dye (Molecular Devices) in a FlexStation 3, as outlined in Knapman 2013. at 37°C for at least 1 hour prior to assay. Fluorescence was measured every 2 seconds (λ excitation = 530nm, λ emission = 565nm, λ emission cut-off = 550nm). Assays were carried out at 37°C and drugs were automatically added in volumes of 20µL.
Determining the Effects of Terpenoids on Acute Hyperpolarization
Terpenoids were added after at least 60 seconds of baseline recording and incubated for 5 minutes before cannabinoid (CP55,940 or Δ 9 -THC) addition. In AtT20-WT cells, somatostatin (SST) was added instead of cannabinoid.
Determining the Effects of Terpenoids on Signalling Desensitization
Homologous desensitization was measured by simultaneously adding Δ 9 -THC with terpenoids after 120 seconds of baseline recording. Signalling desensitization was calculated as percentage decrease from peak Δ 9 -THC response after 30 minutes in drugs. SST (100nM) was added 30 minutes after Δ 9 -THC addition to examine the potential effects of prolonged cannabinoid receptor activation on native somatostatin receptors (heterologous desensitization). The SST response was compared between groups (with or without terpenoids).
Drug Dilution
All drugs (except SST) were made up in DMSO and stored as frozen stocks at a concentration of 10mM -100mM. Terpenoid stock solution concentrations were 100mM, with exception of β-myrcene (30 mM) which was insoluble at 100mM. SST was dissolved in water. Fresh aliquots were used each day, with the drugs diluted in HBSS containing 0.1% bovine serum albumin (Sigma-Aldrich) immediately before the assay. The final concentration of DMSO in each well was 0.1 to 0.11%; this limited the maximum concentration of terpenoids able to be tested. A vehicle (HBSS plus solvent alone) well was included in each column of the 96 well plate and the changes in fluorescence produced by vehicle alone were subtracted before determining the maximum hyperpolarization after each drug exposure. 
Drugs and Reagents
Data Analysis
Each experiment was independently repeated at least 5 times, with 2 technical replicates in each determination. Data are expressed as a percentage change in the fluorescence compared with the predrug baseline (30s before drug addition), or as percentage of 1µM CP55,940 response. Graphs were plotted using Graphpad Prism 7.02, and scatter dot plots show means with standard error of the mean (SEM). Means were compared using unpaired Student's t-test or no matching one-way ANOVA followed by correction for multiple comparisons (Dunnett); and null hypothesis was rejected if p-value was lower than 0.05 (p > 0.05 = not significant).
Results
Terpenoids in AtT20-WT cells
We first examined terpenoid action in non-transfected AtT20 cells. We used somatostatin (100nM) as a positive control because it hyperpolarizes AtT20-WT cells via activation of endogenous SST receptors ( Fig.   1A and B) . 18, 19 Addition of α-pinene, β-pinene, β-caryophyllene, linalool, limonene (100μM) or β-myrcene (30μM) did not affect the membrane potential of AtT20-WT cells (Fig. 1C, open circles) . The presence of terpenoids (100μM/30μM) had no effect on the subsequent somatostatin response (Fig. 1C) .
Terpenoids in AtT20-CB 1 and -CB 2 cells
The absence of a terpenoid response in AtT20-WT cells enabled the study of their effect on membrane potential in AtT20 cells expressing human CB 1 or CB 2 . We examined whether terpenoids (1nM -100μM, β-myrcene 300pM -30μM) hyperpolarised cells via these receptors and, in parallel, whether they affected a subsequent response to a maximally effective concentration of CP55,940 (1µM, Fig. 2 ). 17 A summary of the fluorescence change after terpenoid addition to AtT20-CB 1 cells is shown in Figure 3 (closed circles).
No difference between vehicle and terpenoids was observed. Further, none of the terpenoids changed the membrane potential of cells expressing CB 2 ( Supplementary Fig. S1 ). The change in fluorescence produced by the subsequent addition of the non-selective cannabinoid agonist CP55,940 (1μM) was also unaffected in both AtT20-CB 1 and -CB 2 ( Fig. 3 and Supplementary Fig. S1 -open circles).
CP55,940 is a high efficacy agonist of both CB 1 and CB 2 receptors. 20 However, in Cannabis, ∆ 9 -THC is the principle cannabinoid agonist and it has a lower efficacy than CP55,940, which is apparent in the hyperpolarization assay as a lower maximal response. 20 We next tested the effect of a low and high concentration of terpenoids (100nM and 10μM) on the hyperpolarization produced by three concentrations of ∆ 9 -THC (100nM, 1μM and 10μM). After five minutes of individual terpenoid application, application of ∆ 9 -THC produced fluorescence changes that were not significantly different from those produced by ∆ 9 -THC alone in both AtT20-CB 1 and -CB 2 cells (10μM ∆ 9 -THC Figs. 5 and 6, 100nM ∆ 9 -THC Supplementary Figs. S2 and S3). To explore the possibility of an emergent entourage effect, we combined all six terpenoids (10μM each) and tested the effect of the mixture on the ∆ 9 -THC-induced
hyperpolarization. Similar to individually tested terpenoids, the effects of ∆ 9 -THC were not changed by the mixture (Fig. 7) .
Terpenoids and desensitization in AtT20-CB 1 We have previously reported desensitization cannabinoid-mediated cellular hyperpolarization in AtT20 cells expressing rat or human CB 1 receptors 21, 22 , and we found this reversal of CP55,940-induced hyperpolarization was accelerated by negative allosteric modulators such as ORG27569 and PSNCBAM-1.
Therefore, we tested whether terpenoids may act in a similar way to ORG27569 and other negative allosteric modulators, altering desensitization time-course. We used ∆ 9 -THC instead of CP55,940, as ∆ 9 -THC is the main phytocannabinoid agonist. Prolonged application of ∆ 9 -THC (10μM) produced a hyperpolarization that reversed substantially over 30 minutes. Representative traces for this experiment are illustrated in Figure 8A . We measured the peak response to ∆ 9 -THC and the signal remaining 30 minutes after agonist exposure and quantified desensitization as a percent decline in the peak response.
The ∆ 9 -THC (10μM) signal desensitized by 63.3±6.3%, in the presence of the terpenoid mix desensitization was 60.8±4.9% (Fig. 8B) . Thus, terpenoids did not interfere with desensitization of CB 1 signalling produced by ∆ 9 -THC. We also assessed the capacity of ∆ 9 -THC alone, terpenoids alone (10μM each) or terpenoids combined with ∆ 9 -THC to affect somatostatin receptor signalling in AtT20-CB 1 cells (heterologous desensitization). Somatostatin (100nM) was applied 30 minutes after first drug application (Figs. 8A and 9A and the hyperpolarization produced by somatostatin after ∆ 9 -THC, terpenoids alone or ∆ 9 -THC with terpenoids were not significantly different to somatostatin alone (p > 0.05, Fig. 8B ).
Discussion
The principal finding of this study is that agonist activation of CB 1 and CB 2 receptors is not obviously altered by any or all of the 6 major terpenoids from Cannabis sativa. The terpenoids tested did not activate CB 1 or CB 2 by themselves, nor did they modify the signalling of the high efficacy agonist CP55,940
or the lower efficacy agonist Δ 9 -THC. In particular, Δ 9 -THC effects would be expected to be very sensitive to the presence of drugs which inhibited (or enhanced) signalling at the receptor. There are no spare receptors for Δ 9 -THC in this assay, and changes in ligand binding would be directly reflected as a change in the maximum response. The lack of effect of terpenoids on the response to the synthetic cannabinoid CP55,940 indicates that terpenoids do not interfere with maximal cannabinoid receptor-mediated hyperpolarization, suggesting no direct modulation of the potassium channel response. This was confirmed by the lack of effect of terpenoids on the response to somatostatin.
A previous study provided evidence that β-caryophyllene is a CB 2 agonist 23 . However, we were unable to detect any effect of β-caryophyllene on CB 2 signalling in the present study. The reasons for this are unclear, but the efficacy of β-caryophyllene has not been defined in cellular assays and may be lower than Δ 9 -THC. The CB 2 response to even high concentrations of Δ 9 -THC in our assay is small, suggesting that productive coupling of CB 2 to endogenous potassium channels in AtT-20 cells requires high efficacy agonists. The affinity of β-caryophyllene for CB 2 (155nM) has been determined in membranes from HEK293 cells heterologously expressing CB 2 23 , but is not known in intact cells. Its EC 50 for inhibition of forskolin-induced adenylyl cyclase in CHO-K1 expressing CB 2 was around 2µM, 23 suggesting a low functional affinity, which may not be sufficient to significantly affect the rapid response to the higher affinity agonist Δ 9 -THC.
Positive and negative allosteric modulators have been reported for CB 1 24, 25 , and the effects of several negative allosteric modulators have been defined in the hyperpolarization assay used here. 21 Both PSNCBAM-1 and ORG27569 enhanced CP55,940 signal desensitization, while PSNCBAM-1 also inhibited the initial CP55,940 hyperpolarization. Co-application of the terpenoids with Δ 9 -THC failed to affect the peak response, or the degree of tachyphylaxis observed over a 30-minute exposure to drug, suggesting that they are not acting as allosteric modulators of this CB 1 signalling pathway.
A limitation of the present study is that we only examined CB 1 and CB 2 signalling through one pathway, involving Gi/o. The hyperpolarization of the AtT20 cells likely represents G-protein mediated activation of inwardly rectifying potassium channels (GIRK), as previously described for CB 1 and other GPCR in these cells as well as in several different neurons. 26, 27, 28 Cannabinoid receptors couple to multiple G proteins as well as signalling through other pathways such as those dependent on arrestins and It is possible that entourage effects of terpenoids are mediated through modulation of a subset of the cannabinoid receptor signalling repertoire 26 . CB 1 and CB 2 receptors can be activated in a ligand biased manner -the phenomenon where a drug preferentially activates a subset of the signalling pathways that the receptor can access. 29 In general, this bias has been best defined for G protein coupling versus activation of arrestin-mediated signalling, but to our knowledge there are no examples of cannabinoid ligands only affecting arrestin-mediated signalling. 20, 30 It remains possible that terpenoids have such an absolute bias, but this would be unprecedented, and in any case recruitment of arrestin would be expected to produce enhanced desensitization of the CB 1 responses to prolonged agonist exposure 21, 29 . Any subtle change to receptor signalling should be clear with use of the low efficacy agonist Δ 9 -THC.
Overall, our data suggest that it is unlikely that the terpenoids studied here affect ∆ 9 -THC interactions with cannabinoid receptors. However, this is not a definitive rebuttal of the entourage effect. There are many other ways that these molecules could interact with cannabinoids to influence the overall therapeutic and subjective outcomes of cannabis administration and it should be acknowledged that 
